These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 25090024)

  • 1. Multi-agent chemotherapy overcomes glucocorticoid resistance conferred by a BIM deletion polymorphism in pediatric acute lymphoblastic leukemia.
    Soh SX; Lim JY; Huang JW; Jiang N; Yeoh AE; Ong ST
    PLoS One; 2014; 9(8):e103435. PubMed ID: 25090024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.
    Ng KP; Hillmer AM; Chuah CT; Juan WC; Ko TK; Teo AS; Ariyaratne PN; Takahashi N; Sawada K; Fei Y; Soh S; Lee WH; Huang JW; Allen JC; Woo XY; Nagarajan N; Kumar V; Thalamuthu A; Poh WT; Ang AL; Mya HT; How GF; Yang LY; Koh LP; Chowbay B; Chang CT; Nadarajan VS; Chng WJ; Than H; Lim LC; Goh YT; Zhang S; Poh D; Tan P; Seet JE; Ang MK; Chau NM; Ng QS; Tan DS; Soda M; Isobe K; Nöthen MM; Wong TY; Shahab A; Ruan X; Cacheux-Rataboul V; Sung WK; Tan EH; Yatabe Y; Mano H; Soo RA; Chin TM; Lim WT; Ruan Y; Ong ST
    Nat Med; 2012 Mar; 18(4):521-8. PubMed ID: 22426421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The BIM deletion polymorphism: A paradigm of a permissive interaction between germline and acquired TKI resistance factors in chronic myeloid leukemia.
    Ko TK; Chin HS; Chuah CT; Huang JW; Ng KP; Khaw SL; Huang DC; Ong ST
    Oncotarget; 2016 Jan; 7(3):2721-33. PubMed ID: 26517680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opposing regulation of BIM and BCL2 controls glucocorticoid-induced apoptosis of pediatric acute lymphoblastic leukemia cells.
    Jing D; Bhadri VA; Beck D; Thoms JA; Yakob NA; Wong JW; Knezevic K; Pimanda JE; Lock RB
    Blood; 2015 Jan; 125(2):273-83. PubMed ID: 25336632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bim polymorphisms: influence on function and response to treatment in children with acute lymphoblastic leukemia.
    Gagné V; Rousseau J; Labuda M; Sharif-Askari B; Brukner I; Laverdière C; Ceppi F; Sallan SE; Silverman LB; Neuberg D; Kutok JL; Sinnett D; Krajinovic M
    Clin Cancer Res; 2013 Sep; 19(18):5240-9. PubMed ID: 23908358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer.
    Zhao M; Zhang Y; Cai W; Li J; Zhou F; Cheng N; Ren R; Zhao C; Li X; Ren S; Zhou C; Hirsch FR
    Cancer; 2014 Aug; 120(15):2299-307. PubMed ID: 24737648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition.
    Bachmann PS; Piazza RG; Janes ME; Wong NC; Davies C; Mogavero A; Bhadri VA; Szymanska B; Geninson G; Magistroni V; Cazzaniga G; Biondi A; Miranda-Saavedra D; Göttgens B; Saffery R; Craig JM; Marshall GM; Gambacorti-Passerini C; Pimanda JE; Lock RB
    Blood; 2010 Oct; 116(16):3013-22. PubMed ID: 20647567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucocorticoid-mediated BIM induction and apoptosis are regulated by Runx2 and c-Jun in leukemia cells.
    Heidari N; Miller AV; Hicks MA; Marking CB; Harada H
    Cell Death Dis; 2012 Jul; 3(7):e349. PubMed ID: 22825467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors.
    Kiyota M; Kuroda J; Yamamoto-Sugitani M; Shimura Y; Nakayama R; Nagoshi H; Mizutani S; Chinen Y; Sasaki N; Sakamoto N; Kobayashi T; Matsumoto Y; Horiike S; Taniwaki M
    Apoptosis; 2013 Nov; 18(11):1437-1446. PubMed ID: 23851982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Divergent mechanisms of glucocorticoid resistance in experimental models of pediatric acute lymphoblastic leukemia.
    Bachmann PS; Gorman R; Papa RA; Bardell JE; Ford J; Kees UR; Marshall GM; Lock RB
    Cancer Res; 2007 May; 67(9):4482-90. PubMed ID: 17483364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors.
    Lee JY; Ku BM; Lim SH; Lee MY; Kim H; Kim M; Kim S; Jung HA; Sun JM; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2015 Jun; 10(6):903-9. PubMed ID: 26001141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.
    Nakagawa T; Takeuchi S; Yamada T; Ebi H; Sano T; Nanjo S; Ishikawa D; Sato M; Hasegawa Y; Sekido Y; Yano S
    Cancer Res; 2013 Apr; 73(8):2428-34. PubMed ID: 23382048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of BIM deletion polymorphism on intrinsic resistance and clinical outcome of cancer patient with kinase inhibitor therapy.
    Ying HQ; Chen J; He BS; Pan YQ; Wang F; Deng QW; Sun HL; Liu X; Wang SK
    Sci Rep; 2015 Jun; 5():11348. PubMed ID: 26076815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia.
    Rauzan M; Chuah CT; Ko TK; Ong ST
    PLoS One; 2017; 12(3):e0174107. PubMed ID: 28301600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
    Hall CP; Reynolds CP; Kang MH
    Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer.
    Lee JH; Lin YL; Hsu WH; Chen HY; Chang YC; Yu CJ; Shih JY; Lin CC; Chen KY; Ho CC; Laio WY; Yang PC; Yang JC
    J Thorac Oncol; 2014 Sep; 9(9):1385-92. PubMed ID: 25057939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucocorticoid resistance in chronic lymphocytic leukaemia is associated with a failure of upregulated Bim/Bcl-2 complexes to activate Bax and Bak.
    Melarangi T; Zhuang J; Lin K; Rockliffe N; Bosanquet AG; Oates M; Slupsky JR; Pettitt AR
    Cell Death Dis; 2012 Aug; 3(8):e372. PubMed ID: 22898870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erg and AP-1 as determinants of glucocorticoid response in acute lymphoblastic leukemia.
    Chen DW; Saha V; Liu JZ; Schwartz JM; Krstic-Demonacos M
    Oncogene; 2013 Jun; 32(25):3039-48. PubMed ID: 22869147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MEK inhibitors potentiate dexamethasone lethality in acute lymphoblastic leukemia cells through the pro-apoptotic molecule BIM.
    Rambal AA; Panaguiton ZL; Kramer L; Grant S; Harada H
    Leukemia; 2009 Oct; 23(10):1744-54. PubMed ID: 19404317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The BCL2 rheostat in glucocorticoid-induced apoptosis of acute lymphoblastic leukemia.
    Ploner C; Rainer J; Niederegger H; Eduardoff M; Villunger A; Geley S; Kofler R
    Leukemia; 2008 Feb; 22(2):370-7. PubMed ID: 18046449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.